Sugi Predict

Sugi Predict / Compounds / SCHEMBL408730

SCHEMBL408730

SCHEMBL408730

N#Cc1cc(Cl)cc(CBr)c1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ADRA1D P25100 1/20 0.40
▸ NR3C1 P04150 1/20 0.36
▸ NR3C2 P08235 1/20 0.36
▸ GRM5 P41594 6/20 0.36
▸ MEN1 O00255 1/20 0.34
▸ TTR P02766 1/20 0.34
▸ ALB P02768 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ MRGPRX4 Q96LA9 2/20 0.34
▸ MAOA P21397 1/20 0.33
▸ MAOB P27338 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ S100A9 P06702 1/20 0.33
▸ VCAM1 P19320 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29413304 1.00 ADRA1D (0.40) ADRA1DNR3C1NR3C2GRM5MEN1
SCHEMBL14689467 0.84 TTR (0.41) MEN1TTRALBKMT2AMAOB
SCHEMBL916379 0.84 TTR (0.41) MEN1TTRALBKMT2AMAOB
SCHEMBL27851616 0.84 ADRA1D (0.39) ADRA1DNR3C1NR3C2GRM5MEN1
SCHEMBL5959961 0.81 ADRA1D (0.41) ADRA1DNR3C1NR3C2GRM5MRGPRX4
SCHEMBL25054279 0.79 LOXL2 (0.48) ADRA1DNR3C1NR3C2GRM5MRGPRX4
SCHEMBL2160824 0.79 ADRA1D (0.43) ADRA1DNR3C1NR3C2GRM5MEN1
SCHEMBL30646925 0.79 ADRA1D (0.43) ADRA1DNR3C1NR3C2GRM5MEN1
SCHEMBL501685 0.79 KDM4E (0.41) ADRA1DNR3C1NR3C2GRM5MRGPRX4
SCHEMBL28374391 0.79 ADRA1D (0.40) ADRA1DNR3C1NR3C2GRM5MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4294800-B1 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS INC (US) 2026-05-06 — — EP disclosed
US-20260055083-A1 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS INC (US) 2026-02-26 — — US disclosed
US-12473314-B2 Phospholipid compounds and uses thereof GILEAD SCIENCES, INC. (US) 2025-11-18 — — US disclosed
EP-4573077-A1 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2025-06-25 — — EP disclosed
EP-4537828-A2 PHOSPHOLIPID COMPOUNDS AND USES THEREOF Gilead Sciences, Inc. (US) 2025-04-16 — — EP disclosed
EP-4200301-B1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-02-26 — — EP disclosed
US-20250034182-A1 PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. 2025-01-30 — — US disclosed
US-12180221-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-12-31 — — US disclosed
US-12116380-B2 Phospholipid compounds and methods of making and using the same GILEAD SCIENCES, INC. (US) 2024-10-15 — — US disclosed
US-20240316038-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-09-26 — — US disclosed
EP-2414341-A2 OXADIAZOLE DERIVATIVES Merck Serono SA (CH) 2012-02-08 — — EP disclosed
EP-2414342-A1 OXADIAZOLE DERIVATIVES Merck Serono S.A. (CH) 2012-02-08 — — EP disclosed
US-20120022109-A1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2012-01-26 — — US disclosed
US-20110184029-A1 PYRIDONE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-07-28 — — US disclosed
US-20110184029-A1 PYRIDONE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-07-28 — — US disclosed
US-20110184029-A1 PYRIDONE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-07-28 — — US disclosed
WO-2010115751-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2010-10-14 — — WO disclosed
WO-2010112461-A1 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2010-10-07 — — WO disclosed
US-20100016315-A1 Iminopyridine Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 — — US disclosed
EP-2077262-A1 IMINOPYRIDINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-07-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016315-A1 Iminopyridine Derivative and Use Thereof ADRA1D, ADRB1, ADRB2 ADRA1D 1/4885NR3C1 777/4885NR3C2 137/4885
US-20110184029-A1 PYRIDONE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS DPYD, TYMP, PNPO ADRA1D 2495/4885NR3C1 2201/4885NR3C2 2224/4885
US-12116380-B2 Phospholipid compounds and methods of making and using the same PHOSPHO1, SGMS1, SGMS2 ADRA1D 4552/4885NR3C1 3547/4885NR3C2 2899/4885
US-20260055083-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, LDLR, APOB ADRA1D 162/4885NR3C1 106/4885NR3C2 125/4885
US-20250034182-A1 PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME PHOSPHO1, SGMS1, SGMS2 ADRA1D 4552/4885NR3C1 3547/4885NR3C2 2899/4885
US-12180221-B2 Compounds and uses thereof NLN, ACHE, CLN6 ADRA1D 3723/4885NR3C1 3221/4885NR3C2 2161/4885
US-20120022109-A1 OXADIAZOLE DERIVATIVES OXA1L, HLA-DRB1, SSB ADRA1D 2498/4885NR3C1 535/4885NR3C2 645/4885
US-20240316038-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, SAAL1, APOB ADRA1D 434/4885NR3C1 531/4885NR3C2 250/4885
US-12473314-B2 Phospholipid compounds and uses thereof PHOSPHO1, SGMS2, SGMS1 ADRA1D 4583/4885NR3C1 4229/4885NR3C2 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.